12 Results for "

radiosensitizing effects

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "radiosensitizing effects" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-103241
CAS No.: 293762-45-5
Purity:  99.10%
Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces 42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
loading...
    loading...
Cat. No.: HY-P99866
CAS No.: 1314238-96-4
Synonyms: MEHD-7945A; RG 7597

Target:  

EGFR Akt p38 MAPK Apoptosis

Research Areas:  

Cancer

Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research .
loading...
    loading...
Cat. No.: HY-P99296
CAS No.: 725735-28-4
Synonyms: CNTO 95; Anti-Human CD51 Recombinant Antibody

Target:  

Integrin Apoptosis

Research Areas:  

Cancer

Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
loading...
    loading...
Cat. No.: HY-124813
CAS No.: 2083618-79-3
Purity:  99.29%
Synonyms: 113B7
Target:  

FAK EGFR MMP NF-κB SDCBP

Research Areas:  

Cancer

PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-105061
CAS No.: 13551-87-6
Synonyms: Ro 7-0582; SR 1354
Target:  

Bacterial Parasite

Research Areas:  

Infection Cancer

Misonidazole (Ro 7-0582; SR 1354) is a hypoxic tumor cell radiosensitizer . Misonidazole also has antimicrobial effects .
loading...
    loading...
Cat. No.: HY-123292
CAS No.: 88876-94-2
Research Areas:  

Cancer

RSU 1164 is a radiosensitizer and chemopotentiator. RSU 1164 has anticancer effects .
loading...
    loading...
Cat. No.: HY-121648
CAS No.: 140448-29-9
Research Areas:  

Cancer

PK 130 is a 2-nitroimidazole derivative that has radiosensitizing effects on hypoxic cells. PK 130 increases the radiosensitivity of Chinese hamster V79 cells under hypoxic conditions .
loading...
    loading...
Cat. No.: HY-118988
CAS No.: 292615-75-9
Target:  

PPAR Apoptosis

Research Areas:  

Cancer

CAY10506 is a PPARγ ligand that can induce cell death and ROS production in a PPARγ-dependent manner in vitro. CAY10506 exhibits radiosensitizing effects, enhancing γ-radiations-induced apoptosis and caspase-3-mediated poly (ADP-ribose) polymerase (PARP) cleavage. CAY10506 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-W177315A
CAS No.: 55747-72-3
Research Areas:  

Cancer

5-Nitrotryptamine is a radiosensitizer. 5-Nitrotryptamine shows radiosensitizing effects. 5-Nitrotryptamine can be used in the research of hypoxic tumors .
loading...
    loading...
Cat. No.: HY-103241R
CAS No.: 293762-45-5
Ro 90-7501 (Standard) is the analytical standard of Ro 90-7501 (HY-103241). This product is intended for research and analytical applications. Ro 90-7501 is an amyloid β42 (Aβ42) fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC50 of 2 μM). Ro 90-7501 inhibits ATM phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .
loading...
    loading...
Cat. No.: HY-15772G
CAS No.: 1421373-65-0
Synonyms: AZD-9291 (GMP); Mereletinib (GMP)
Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib (HY-15772). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-15772GL
CAS No.: 1421373-65-0
Synonyms: AZD-9291 (GMP Like); Mereletinib (GMP Like)
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFR T790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer .
loading...
    loading...
  • 1